The FDA set up a new Web page to provide postmarket drug safety information to patients and providers.
The Food and Drug Administration (FDA) set up a new Web page to provide postmarket drug safety information to patients and providers, American Medical News (11/17/08) reported. The Web site, http://www.fda.gov/cder/drugsafety.htm, was created under the requirements of the FDA Amendments Act of 2007 and enacted last fall to correct drug safety problems.
The site provides links to a variety of information, including drug labeling; medications that have risk evaluation and mitigation strategies; FDA-required postmarket studies and clinical trials of approved products; registry of federally and privately supported clinical trials; and the latest safety information. Included are an index to drug-specific information, drug safety announcements, medical product safety information from MedWatch, and new safety information identified by the Adverse Event Reporting System. Site users also can link to MedWatch, information about warnings and recalls, regulations and guidance documents, general health information, and consumer and professional articles about using medicines safely.
Study highlights need for interventions to prevent postpartum smoking relapse
January 21st 2025Smoking cessation during pregnancy not only reduces pregnancy complications but also lowers the risk of relapse and new smoking initiation in the first postpartum year, according to a recent study.
Read More
USPSTF recommends osteoporosis screening for senior women to prevent fractures
January 20th 2025The US Preventive Services Task Force emphasizes screening for osteoporosis in women aged 65 years and older and at-risk postmenopausal women aged under 65 years, citing moderate benefits in fracture prevention.
Read More